In managing a patient with an acute severe asthma exacerbation, which agent is preferred for induction during intubation?

In the context of managing an acute severe asthma exacerbation, ketamine is the preferred agent for induction during intubation due to its unique properties. Ketamine is a dissociative anesthetic that provides rapid sedation while simultaneously preserving airway reflexes and respiratory drive. This is particularly advantageous in patients with asthma, as they are often hyperreactive and may experience further bronchospasm with certain anesthetic agents.

Additionally, ketamine has bronchodilatory effects, directly acting on the bronchial smooth muscle, which can alleviate bronchospasm and improve ventilation during a critical moment such as intubation. Its use can also mitigate the complications that could arise from intubating a patient who is already experiencing respiratory distress.

While other agents like etomidate, midazolam, and propofol are effective sedatives, they do not carry the same beneficial features for patients with asthma exacerbations. Etomidate does not provide significant bronchodilation and could potentially lead to airway reflex suppression. Midazolam, while commonly used for sedation, can cause respiratory depression and increase the risk of airway complications. Propofol, although a rapid-acting sedative, can further depress respiratory function without the protective airway reflexes beneficial in this scenario.

In